Johnson & Johnson vs Merck & Co., Inc.
JNJ vs MRK — side-by-side comparison from reported financials. JNJ leads 9, MRK leads 2 of 11 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Merck & Co., Inc.
MRK · Healthcare
$146.33+2.77%Mixed
| Metric | JNJ | MRK |
|---|---|---|
| Price | $261.79 | $146.33 |
| Market cap | $631B | $361B |
| Revenue (TTM) | $97.9B | $66.6B |
| Revenue growth | +5.6% | +3.1% |
| Net margin | 21.5% | 4.8% |
| Free cash flow | $22.2B | $16.1B |
| Net cash (debt) | ($27.8B) | ($34.8B) |
| 1-year price return | +37.0% | +67.2% |
| P/E | 29.9 | 113.2 |
| P/E vs own history (cheap-side %) | 16% | 7% |
| Dividend yield | 2.00% | 2.31% |
| Return on equity | 26% | 7% |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 140,800 | 75,000 |
Full résumé-style profiles: JNJ CV · MRK CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.